About MACUGEN^® (pegaptanib sodium injection)

If you have wet age-related macular degeneration (AMD), it is important to understand your treatment so that you, along with your doctor, can do everything possible to achieve the best outcome. In this web site, you will find information on an innovative treatment for wet AMD called MACUGEN (pegaptanib sodium injection). MACUGEN can help you preserve your vision by slowing vision loss.

In December 2004, MACUGEN became the first anti-VEGF inhibitor to be approved by the FDA for the treatment of wet AMD. While MACUGEN is effective at slowing vision loss, it's still important to detect wet AMD as early as possible to help preserve vision.

For example, MACUGEN treatment given every 6 weeks for up to 2 years has been shown to significantly reduce the risk of moderate vision loss in patients with all types of wet AMD. Data suggests that patients who had early wet AMD and were treated with MACUGEN had improved vision outcomes than those who started treatment later. These kinds of results highlight the importance of beginning treatment before wet AMD becomes advanced and routine activities become difficult.

Learn more about WET AMD

 

   

Email this page Print this page

To listen to the full prescribing information regarding MACUGEN, please click on the link entitled "Important Safety Information" on the menu bar located on the left of the screen.